 MINNEAPOLIS, Jan. 26, 2021 GLOBE NEWSWIRE -- Predictive Oncology Inc. NASDAQ: POAI Predictive Oncology or the Company, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 3,414,970 shares of its common stock, at a purchase price of 1.20 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were approximately 4.1 million, before deducting the placement agents fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,707,485 shares of common stock at an exercise price of 1.37 per share. The warrants are exercisable immediately upon issuance and have a term and five and one-half years. 